Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
2001 1
2002 4
2003 2
2004 2
2005 1
2006 1
2007 2
2009 1
2010 2
2013 2
2014 1
2015 2
2016 3
2017 2
2018 5
2019 2
2020 1
2021 3
2022 3
2023 3
2024 5
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Kirste S, Jacobasch L, Allgäuer M, Flentje M, Germer CT, Grützmann R, Hildebrandt G, Schwarzbach M, Bechstein WO, Sülberg H, Friede T, Gaedcke J, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group. Fokas E, et al. JAMA Oncol. 2022 Jan 1;8(1):e215445. doi: 10.1001/jamaoncol.2021.5445. Epub 2022 Jan 20. JAMA Oncol. 2022. PMID: 34792531 Free PMC article. Clinical Trial.
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214).
Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, Kubicka S, Kochen L, Merx K, Krause K, Ebert M, Rödel C, Fokas E, Ghadimi M, Reissfelder C, Gaiser T. Hofheinz RD, et al. Among authors: merx k. ESMO Open. 2024 Sep;9(9):103703. doi: 10.1016/j.esmoop.2024.103703. Epub 2024 Sep 10. ESMO Open. 2024. PMID: 39260162 Free PMC article. Clinical Trial.
Differential effects of sound interventions tuned to 432 Hz or 443 Hz on cardiovascular parameters in cancer patients: a randomized cross-over trial.
Hohneck A, Rodríguez ÁM, Weingärtner S, Merx K, Sarodnick F, von Gagern F, Mavratzas A, Burkholder I, Schumacher G, Hofmann WK, Hofheinz RD. Hohneck A, et al. Among authors: merx k. BMC Complement Med Ther. 2025 Jan 22;25(1):18. doi: 10.1186/s12906-025-04758-5. BMC Complement Med Ther. 2025. PMID: 39844155 Free PMC article. Clinical Trial.
Diagnosis and therapy of polycythemia vera.
Lengfelder E, Merx K, Hehlmann R. Lengfelder E, et al. Among authors: merx k. Semin Thromb Hemost. 2006 Apr;32(3):267-75. doi: 10.1055/s-2006-939438. Semin Thromb Hemost. 2006. PMID: 16673281 Review.
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
Hofheinz RD, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, Kretzschmar A, Teschendorf C, Siegler G, Ebert MP, Goekkurt E, Mahlberg R, Homann N, Pink D, Bechstein W, Reichardt P, Flach H, Gaiser T, Battmann A, Oduncu FS, Loose M, Sookthai D, Pauligk C, Göetze TO, Al-Batran SE. Hofheinz RD, et al. Among authors: merx k. J Clin Oncol. 2022 Nov 10;40(32):3750-3761. doi: 10.1200/JCO.22.00380. Epub 2022 Jun 16. J Clin Oncol. 2022. PMID: 35709415 Clinical Trial.
49 results